On August 5, Novo-Nordisk A/S rose 5.04% in pre-market trading, trading at approximately $45.50/share, with turnover of $999,200.

The move was driven by the company releasing Q2 results that significantly exceeded market expectations. Adjusted EPS came in at $0.96, beating the consensus estimate of $0.81 by 18.5%, while sales of $12.209 billion also surpassed the $11.35 billion estimate. The company simultaneously raised its full-year adjusted sales and operating profit guidance, with the upward revision primarily driven by higher GLP-1 product sales expectations.

The strong quarterly performance represents a recovery from last week's sharp sell-off when the stock plunged nearly 10% after its cardiovascular drug candidate ziltivekimab failed to meet the primary endpoint in a Phase 3 trial. Management struck a confident tone on the earnings call, noting that oral Wegovy has captured approximately 90% of the oral obesity drug market with 1.5 million patients globally, while the CEO reaffirmed confidence in the company's pipeline. However, some investors noted that Wegovy oral sales of 32.2 billion Danish kroner slightly missed the 33.2 billion estimate, and US injectable Wegovy sales also underperformed expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)